Ja lap , aan 4,13 euro per aandeel ......Liege, Belgium, 30 November 2022 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company dedicated to Women’s Health, today announces that, following the first and second drawdowns by the Company under the loan facility concluded with funds managed by Highbridge Capital Management, LLC ("Highbridge") and funds managed by Whitebox Advisors, LLC ("Whitebox", and together with Highbridge, each a “Lender”), another portion of the loans was contributed in kind by Highbridge against the issuance of new shares.
Following the first and second drawdowns, another portion of the loans (including accrued interest, as relevant, and an option payment amount) was contributed in kind for an aggregate amount of EUR 2,607,005.71 through the issuance of 631,359 new shares at an issue price of ca. EUR 4.13 per share. Following the last contribution in kind, the outstanding principal amount of the loans already drawn is EUR 54,826,161.29.